Sleep Apnea and Heart Risk: Why Do Oxygen Drops Matter?

Medically reviewed | Published: | Evidence level: 1A
Headlines about experimental sleep apnea medicines raise a broader question: which improvements during sleep translate into better long-term health? Observational studies associate the depth and duration of oxygen drops with cardiovascular risk, but improving these measurements does not by itself prove that a treatment prevents heart attacks.
📅 Published:
Reviewed by iMedic Medical Editorial Team
📄 Cardiovascular Health

Quick Facts

2025 Study Participants
4,396 adults
Median Follow-up
Over 11 years
Study Design
Observational cohort analysis

What Does Hypoxic Burden Measure in Sleep Apnea?

Quick answer: Hypoxic burden measures the cumulative depth and duration of oxygen drops associated with breathing interruptions during sleep.

Sleep apnea reports commonly feature the apnea-hypopnea index, or AHI: the number of complete or partial breathing interruptions per hour of sleep. That count helps characterize the condition, but it does not fully describe the oxygen disturbance accompanying each event. Hypoxic burden combines information about the depth and duration of event-related oxygen drops across the night. Two people with similar event counts can therefore have different oxygen burdens. Researchers developed this measurement to capture information that a frequency count alone can miss. [European Heart Journal study](https://pubmed.ncbi.nlm.nih.gov/30376054/).

The distinction is relevant to recent coverage of experimental oral treatment AD109. Its 26-week SynAIRgy trial evaluated breathing interruptions and oxygen measures, including hypoxic burden. Those measurements help establish whether a treatment improves nighttime breathing; they do not establish that it prevents cardiovascular deaths. The study's reported efficacy endpoints addressed sleep apnea physiology and symptoms, rather than demonstrating fewer heart attacks or strokes. Interpreting a promising treatment therefore requires separating the outcomes actually measured from benefits that remain to be tested. [SynAIRgy trial](https://pubmed.ncbi.nlm.nih.gov/42148495/).

How Strong Is the Link Between Oxygen Drops and Heart Risk?

Quick answer: Several observational analyses link greater hypoxic burden with cardiovascular risk, although findings vary across patient groups.

A 2025 analysis in ERJ Open Research examined 4,396 Sleep Heart Health Study participants who initially had no cardiovascular disease, with median follow-up exceeding 11 years. Greater hypoxic burden was associated with cardiovascular mortality independently of symptom patterns. Excessive sleepiness also carried information about cardiovascular risk. However, within the subgroup with moderate to severe obstructive sleep apnea, hypoxic burden was not associated with the cardiovascular outcomes examined. That limitation argues against treating one oxygen measurement as a universal predictor. [Mazzotti and colleagues](https://pubmed.ncbi.nlm.nih.gov/40008168/).

Earlier work published in the European Heart Journal in 2019 analyzed 2,743 older men and 5,111 middle-aged and older adults from two community cohorts. Greater hypoxic burden predicted cardiovascular mortality in both cohorts. Together, these findings support studying oxygen disturbances alongside event counts and symptoms. They remain observational evidence: statistical adjustment cannot eliminate every alternative explanation, and an association does not prove that lowering the measurement with a particular treatment will prevent cardiovascular disease. [Azarbarzin and colleagues](https://pubmed.ncbi.nlm.nih.gov/30376054/).

What Should Patients Ask About Their Sleep Study Results?

Quick answer: Ask how breathing events, oxygen levels, symptoms and medical history together affect your diagnosis and treatment plan.

A sleep study provides information about breathing and blood oxygen that clinicians interpret alongside symptoms, examination findings and medical history. Useful questions include whether oxygen drops occurred with breathing interruptions, whether the results adequately explain persistent sleepiness, and how treatment effectiveness will be assessed. The National Heart, Lung, and Blood Institute describes sleep studies as central to diagnosing sleep apnea and determining its type and severity. A single number should be discussed in that broader clinical context. [NHLBI diagnosis guidance](https://www.nhlbi.nih.gov/health/sleep-apnea/diagnosis).

Treatment decisions should also account for whether a person can use the recommended therapy consistently. Positive airway pressure keeps the airway open during sleep; other options include fitted oral appliances and selected procedures. NHLBI advises that oral devices may be considered when someone cannot tolerate or does not want to use CPAP. Continuing difficulty with treatment warrants a review of available options. A headline about improved oxygen measurements provides a reason to discuss emerging evidence, but it does not establish that an existing treatment should be stopped or replaced. [NHLBI treatment guidance](https://www.nhlbi.nih.gov/health/sleep-apnea/treatment).

Frequently Asked Questions

No. The lowest reading describes one point during the night. Hypoxic burden integrates the depth and duration of oxygen drops associated with breathing events. [European Heart Journal study](https://pubmed.ncbi.nlm.nih.gov/30376054/).

No. Improved oxygen measurements demonstrate a physiological effect. Establishing cardiovascular protection requires evidence about outcomes such as heart attacks, strokes or cardiovascular deaths; the reported SynAIRgy efficacy results did not establish those benefits. [SynAIRgy trial](https://pubmed.ncbi.nlm.nih.gov/42148495/).

No. The 2025 analysis found that oxygen burden and symptom patterns provided different information, and results varied by subgroup. Neither should be interpreted as a complete assessment by itself. [ERJ Open Research study](https://pubmed.ncbi.nlm.nih.gov/40008168/).

References

  1. Strollo PJ Jr, et al. Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy). American Journal of Respiratory and Critical Care Medicine. 2026;212(7):1569-1584. [doi:10.1093/ajrccm/aamag215](https://pubmed.ncbi.nlm.nih.gov/42148495/).
  2. Mazzotti DR, et al. OSA symptom subtypes and hypoxic burden independently predict distinct cardiovascular outcomes. ERJ Open Research. 2025;11(1):00511-2024. [doi:10.1183/23120541.00511-2024](https://pubmed.ncbi.nlm.nih.gov/40008168/).
  3. Azarbarzin A, et al. Study of sleep apnea hypoxic burden and cardiovascular mortality in the MrOS and Sleep Heart Health Study cohorts. European Heart Journal. 2019;40(14):1149-1157. [doi:10.1093/eurheartj/ehy624](https://pubmed.ncbi.nlm.nih.gov/30376054/).
  4. National Heart, Lung, and Blood Institute. [Sleep Apnea: Diagnosis](https://www.nhlbi.nih.gov/health/sleep-apnea/diagnosis).
  5. National Heart, Lung, and Blood Institute. [Sleep Apnea: Treatment](https://www.nhlbi.nih.gov/health/sleep-apnea/treatment).